Quince Therapeutics News and Activities

Quince Therapeutics is a company listed under the stock ticker CRTX (US).

Acquisition, funding and merger involving Quince Therapeutics.

• Quince Therapeutics has announced the acquisition of OrphAI Therapeutics  (posted on May 19 2026).

View the org chart displaying its 18 main executives

Most searched biographies at Quince Therapeutics

• Dirk Thye, Chief Executive Officer and Director
• David Lamond, Chairman of the Board
• Una Ryan, Director

Create your alert
to follow the executive moves at Quince Therapeutics.

Quince Therapeutics has 3,509 competitors including UnitedHealth Group (United States (USA)), Kaiser Permanente (United States (USA)) and HCA (United States (USA)).

Popular M&A news in Healthcare

• Adaptive Innovations has just announced a $50 Million fundraising (posted on June 4 2026).
• Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
• Freeman Health System has acquired Northwest Health (posted on June 2 2026).

Popular contacts in Healthcare

• Ari Bousbib - Chairman and Chief Executive Officer at IQVIA
• Gregory Adams - Chief Executive Officer and Chairman of the Board at Kaiser Permanente
• Pablo Legorreta - Chairman of the Board, Founder and Chief Executive Officer at Royalty Pharma

Learn more about the Healthcare industry

Press releases by Quince Therapeutics

• Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline | Quince Therapeutics
• Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD | Quince Therapeutics
• Quince Therapeutics Settles Approximately $16.4 Million of Debt | Quince Therapeutics
• Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives | Quince Therapeutics
• Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia | Quince Therapeutics
• Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting | Quince Therapeutics
• Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia | Quince Therapeutics
• Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders | Quince Therapeutics
• News Releases | Quince Therapeutics
• Quince Therapeutics to Participate at Investor Events in December 2025 | Quince Therapeutics
• View more press releases Close

Social media about Quince Therapeutics

• Quince Therapeutics on Wikipedia, Google News & Yahoo Finance
• Quince Therapeutics on LinkedIn, X (Twitter) & YouTube